Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases

NCT07392528 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Neuromyelitis Optica Spectrum Disorders
Multiple Sclerosis
Myasthenia Gravis

Interventions

DRUG: QT-019C

Sponsor

Tianjin Huanhu Hospital